Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation
Clinical Pharmacokinetics · 2024
DOI: 10.1007/s40262-023-01335-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Jingcheng Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Bill & Melinda Gates Foundation, National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Recent research indicates a correlation between plasma concentration of P2Y12 inhibitors and clinical events, particularly bleeding, which significantly impeded their clinical therapeutic performance. It is therefore vital to delve into the factors that might affect the plasma concentration. The study aims to summarize population pharmacokinetics/pharmacodynamics (PopPKPD) models for commonly prescribed P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) and assess bleeding risk in specific individual groups. METHODS: The PopPKPD models of P2Y12 inhibitors were collected and summarized based on predetermined inclusion and exclusion criteria. The collected models were replicated in simulations, which were used to assess factors affecting plasma concentrations of P2Y12 inhibitors. Simulation results for special populations were compared to therapeutic window based on reported exposure-effect relationships (PK/PD-related bleeding and thrombotic clinical outcomes) to predict bleeding risk in special populations with different dosing regimens and cumulative covariates. RESULT: Finally, 12 studies were included for PK simulation, 7 of which that also included PD data were subjected to further analysis, with the majority being based on Phase I or II trials. Simulations showed that several covariates such as female gender, weight, elderly can significantly impact on exposure, with special populations reaching up to 179% of the general population. However, after dose adjustment, blood concentrations for special populations can reach approximately ±20% of general population exposure. Therefore, lowering the maintenance dose of ticagrelor from 90 to 60 mg bid was first recommended to reduce bleeding risk without significantly increasing ischemic risk, particularly in elderly, small-weight Asian females. CONCLUSION: Lowering the maintenance dose of ticagrelor from 90 to 60 mg bid effectively reduces bleeding risk without increasing thrombotic infarction risk in elderly, small-weight Asian females.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
- Center of Clinical Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
- Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China. cuicheng1226@163.com.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. cuicheng1226@163.com.
ORCID-Profile: Dongyang Liu
Förderung
- Bill & Melinda Gates Foundation
- National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- Bill and Melinda Gates Foundation
Zitieren
APA
Chen, J., Qu, Y., Jiang, M., Li, H., Cui, C., & Liu, D. (2024). Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-023-01335-2
Vancouver
Chen J, Qu Y, Jiang M, Li H, Cui C, Liu D. Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-023-01335-2
BibTeX
@article{Chen2024,
author = {Chen, Jingcheng and Qu, Yuchen and Jiang, Muhan and Li, Haiyan and Cui, Cheng and Liu, Dongyang},
title = {Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation},
journal = {Clinical Pharmacokinetics},
year = {2024},
doi = {10.1007/s40262-023-01335-2}
}
EUVIMED